Denali Therapeutics (DNLI)

• Market cap: $1.94B
• 1 day: 0.76%
• 5 days: -13.56%
• 1 month: -10.53%
• 3 months: -9.3%
• 6 months: -14.12%
• Year to date: -36.37%
• 1 year: -56.28%
• 5 years: -65.33%
• 10 years: -38.18%
• Sector: Healthcare
• Industry: Biotechnology

About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Employees: 486

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

230% more call options, than puts

Call options by funds: $2.08M | Put options by funds: $630K

30% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 64

28% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 36

7% more capital invested

Capital invested by funds: $1.81B [Q1] → $1.93B (+$118M) [Q2]

4% more funds holding

Funds holding: 221 [Q1] → 230 (+9) [Q2]

3.21% more ownership

Funds ownership: 91.5% [Q1] → 94.71% (+3.21%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $30
• Avg. target: $30
• High target: $30

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Morgan Stanley Matthew Harrison

$30

Overweight Maintained

18 Aug 2025